Zentalis Pharmaceuticals (NASDAQ:ZNTL) Now Covered by Analysts at Leerink Partners

Leerink Partners initiated coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research note issued to investors on Monday morning, MarketBeat.com reports. The firm issued an outperform rating and a $8.00 price target on the stock.

Other research analysts have also recently issued reports about the company. Rodman & Renshaw started coverage on Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They issued a “buy” rating and a $11.00 target price for the company. Wall Street Zen lowered Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Mizuho began coverage on Zentalis Pharmaceuticals in a research report on Friday, July 17th. They issued an “outperform” rating and a $8.00 price objective for the company. William Blair began coverage on Zentalis Pharmaceuticals in a research report on Wednesday, September 16th. They issued an “outperform” rating for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Friday. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.50.

Zentalis Pharmaceuticals Stock Up 10.3%

Shares of ZNTL stock opened at $2.78 on Monday. Zentalis Pharmaceuticals has a 12-month low of $1.21 and a 12-month high of $6.95. The firm has a market capitalization of $199.24 million, a price-to-earnings ratio of -1.43 and a beta of 1.93. The firm has a fifty day moving average of $3.71 and a 200-day moving average of $3.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). Research analysts expect that Zentalis Pharmaceuticals will post -2.11 earnings per share for the current year.

Insider Activity

In other news, major shareholder Group Walters purchased 4,335,000 shares of the company’s stock in a transaction on Friday, August 14th. The shares were purchased at an average price of $3.50 per share, with a total value of $15,172,500.00. Following the purchase, the insider directly owned 17,844,973 shares of the company’s stock, valued at $62,457,405.50. This trade represents a 32.09% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 3.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. 5AM Venture Management LLC raised its position in Zentalis Pharmaceuticals by 705.7% in the 4th quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock valued at $5,330,000 after buying an additional 3,457,913 shares during the last quarter. BlackRock Inc. acquired a new position in Zentalis Pharmaceuticals during the 2nd quarter worth approximately $18,205,000. Ishara Investments LP acquired a new position in Zentalis Pharmaceuticals during the 4th quarter worth approximately $1,782,000. Bank of America Corp DE bought a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $5,406,000. Finally, Primecap Management Co. CA bought a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $4,643,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research programs are designed to target biological pathways involved in tumor growth, survival and resistance to existing therapies.

Zentalis’ lead investigational product is azenosertib, also known as ZN-c3, an oral WEE1 inhibitor being evaluated in clinical trials for several advanced cancers.